Maverick reports 2.3% Rocket Pharmaceuticals (RCKT) stake in Schedule 13G/A

Rhea-AI Filing Summary

Maverick Capital and related entities filed an amended Schedule 13G reporting their beneficial ownership of Rocket Pharmaceuticals common stock. They report beneficial ownership of 2,513,110 shares of Rocket, representing 2.3% of the outstanding common stock, based on 108,222,228 shares outstanding as of October 31, 2025.

The shares are held for Maverick’s investment advisory clients, including Maverick HP, L.P. with 1,917,698 shares and certain separately managed accounts with 595,412 shares. The filers certify that the securities were not acquired to change or influence control of Rocket Pharmaceuticals.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Rocket Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, $0.01 par value per share

(Title of Class of Securities)

77313F106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Maverick Capital, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,513,110.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,513,110.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,513,110.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Maverick Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,513,110.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,513,110.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,513,110.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 77313F106

1

Names of Reporting Persons

Lee S. Ainslie III

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,513,110.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,513,110.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,513,110.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rocket Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 9 Cedarbrook Drive, Cranbury, NJ 08512
Item 2.
(a)	Name of person filing: This Schedule 13G (the "Schedule 13G") is being filed on behalf of each of the following persons (each, a "Reporting Person") with respect to shares of Common Stock, $0.01 par value per share (the "Shares") of Rocket Pharmaceuticals, Inc. (the "Issuer"): Maverick Capital, Ltd. ("Maverick"); Maverick Capital Management, LLC ("Maverick Capital Management"); and Lee S. Ainslie III ("Mr. Ainslie"). This Schedule 13G relates to Shares held for the accounts of Maverick's clients.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of (i) Maverick and Maverick Capital Management is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.
(c)	Citizenship: Maverick is a Texas limited partnership; Maverick Capital Management is a Texas limited liability company; and Mr. Ainslie is a United States citizen.
(d)	Title of class of securities: Common stock, $0.01 par value per share
(e)	CUSIP No.: 77313F106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Ownership as of December 31, 2025 is incorporated by reference to items 5 - 9 and 11 of the cover page of each of the Reporting Person. The ownership percentages are based on 108,222,228 outstanding Shares of the Issuer as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. Maverick is the investment advisor of (i) Maverick HP, L.P., a Delaware limited partnership, which holds 1,917,698 Shares, and (ii) certain separately managed accounts which collectively hold 595,412 Shares. Maverick is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the Shares which are the subject of this filing through the investment discretion it exercises over its clients' accounts. Maverick Capital Management is the General Partner of Maverick. Mr. Ainslie is the manager of Maverick Capital Management.
(b)	Percent of class: The information set forth in item 11 of the cover pages to the Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information set forth in item 5 of the cover pages to the Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information set forth in item 6 of the cover pages to the Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information set forth in item 7 of the cover pages to the Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information set forth in item 8 of the cover pages to the Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Maverick Capital, Ltd.

Signature:	/s/ Trevor Wiessmann*
Name/Title:	By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager
Date:	02/13/2026

Maverick Capital Management, LLC

Signature:	/s/ Trevor Wiessmann*
Name/Title:	Lee S. Ainslie III, Manager
Date:	02/13/2026

Lee S. Ainslie III

Signature:	/s/ Trevor Wiessmann*
Name/Title:	Lee S. Ainslie III
Date:	02/13/2026

Comments accompanying signature: *Under Power of Attorney, dated March 15, 2018

FAQ

What ownership stake in Rocket Pharmaceuticals (RCKT) does Maverick report?

Maverick and related entities report beneficial ownership of 2,513,110 Rocket shares, representing 2.3% of the common stock. This percentage is based on 108,222,228 shares outstanding as of October 31, 2025, from Rocket’s Form 10-Q.

Which Maverick accounts hold Rocket Pharmaceuticals (RCKT) shares?

Rocket shares are held for Maverick’s advisory clients, including Maverick HP, L.P. with 1,917,698 shares and certain separately managed accounts collectively holding 595,412 shares. Maverick may be deemed a beneficial owner through its investment discretion.

Who are the reporting persons on this Rocket Pharmaceuticals (RCKT) Schedule 13G/A?

The filing lists three reporting persons: Maverick Capital, Ltd., Maverick Capital Management, LLC, and Lee S. Ainslie III. Maverick is the investment adviser, Maverick Capital Management is its general partner, and Ainslie is the manager of Maverick Capital Management.

Does Maverick seek to influence control of Rocket Pharmaceuticals (RCKT)?

The filers certify the Rocket shares were not acquired and are not held for changing or influencing control of Rocket Pharmaceuticals. They also state the holdings are not in connection with any transaction having that control-related purpose or effect.

What type of filing did Maverick submit for Rocket Pharmaceuticals (RCKT)?

Maverick and related parties submitted an Amendment No. 2 to Schedule 13G regarding Rocket’s common stock. A Schedule 13G/A is a beneficial ownership report generally used for passive holdings below certain control-related thresholds.

As of what date is Maverick’s Rocket Pharmaceuticals (RCKT) ownership calculated?

The ownership calculation uses 108,222,228 Rocket shares outstanding as of October 31, 2025, as reported in Rocket’s Form 10-Q filed on November 6, 2025. Beneficial ownership is reported as of December 31, 2025.